Kiniksa Pharmaceuticals International PLC KNSA.OQ KNSA.O is expected to show a rise in quarterly revenue when it reports results on February 24 for the period ending December 31 2025
The London United Kingdom-based company is expected to report a 59.1% increase in revenue to $195.005 million from $122.54 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Kiniksa Pharmaceuticals International PLC is for earnings of 37 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $56.50, about 19.8% above its last closing price of $47.17
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | 0.32 | 0.32 | 0.23 | Missed | -28.9 |
Jun. 30 2025 | 0.17 | 0.18 | 0.23 | Beat | 26.3 |
Mar. 31 2025 | -0.01 | 0.04 | 0.11 | Beat | 161.9 |
Dec. 31 2024 | -0.10 | 0.00 | -0.12 | Missed | -5,900 |
Sep. 30 2024 | -0.02 | 0.03 | -0.18 | Missed | -662.5 |
Jun. 30 2024 | -0.07 | -0.07 | -0.06 | Beat | 20 |
Mar. 31 2024 | -0.16 | -0.16 | -0.25 | Missed | -53.1 |
Dec. 31 2023 | -0.12 | -0.14 | 0.35 | Beat | 350 |
This summary was machine generated February 20 at 13:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)